Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with ‘‘what-ifs’’

Author： Surh Linda C   Lesko Lawrence J   Hobbs Stuart   Gutman Steve   Minasian Lori M   Pasqua Oscar E Della   Austin MJ Finley   Lu Kan  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.1, 2009-01, pp. : 137-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Current pharmacogenomic approaches to clinical drug development

By Murphy Michael P  

Pharmacogenomics, Vol. 1, Iss. 2, 2000-05 ,pp. : 115-123

Future Medicine

Access to resources Recommend Favorite

Perspectives on development of a combination pharmacogenomic diagnostic and drug product

By McCamish Mark   Izumi Raquel  

Pharmacogenomics, Vol. 7, Iss. 7, 2006-10 ,pp. : 1045-1049

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomic biomarkers for personalized medicine

By Chen James J   Lin Wei-Jiun   Chen Hung-Chia  

Pharmacogenomics, Vol. 14, Iss. 8, 2013-06 ,pp. : 969-980

Future Medicine

Access to resources Recommend Favorite

Auflistung der U.S. Food and Drug Administration: Pharmacogenomic Biomarkers in Drug Labels

By  

PHARMAKON, Vol. 1, Iss. 1, 2013-01 ,pp. : 36-39

Govi-Verlag

Access to resources Recommend Favorite

Mobilizing pharmacogenomic analyses during clinical trials in drug development

By Bienfait Karina L   Shaw Peter M   Murthy Gowri   Warner Amelia Wall  

Pharmacogenomics, Vol. 14, Iss. 10, 2013-07 ,pp. : 1227-1235

Future Medicine

Access to resources Recommend Favorite